Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1, First in Human, Open Label, Dose Escalation Study of AMV564, a CD33 x CD3 Tandem Diabody in Patients With Relapsed or Refractory Acute Myeloid Leukemia

NCT03144245 is registered in ClinicalTrials.gov with Amphivena Therapeutics, Inc. as lead sponsor.

NCT NCT03144245
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03144245 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1, First in Human, Open Label, Dose Escalation Study of AMV564, a CD33 x CD3 Tandem Diabody in Patients With Relapsed or Refractory Acute Myeloid Leukemia
Lead sponsor
Amphivena Therapeutics, Inc.
Phase
Phase 1
Overall status
Completed
Start date
March 20, 2017
Completion date
November 5, 2020
Enrollment
53 (actual)
Sites
10

Conditions

As the registry lists them; a condition with its own page is linked.

acute myeloid leukemia